{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:26:15Z","timestamp":1773210375718,"version":"3.50.1"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY19B020008"],"award-info":[{"award-number":["LY19B020008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2217710 5"],"award-info":[{"award-number":["2217710 5"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877101"],"award-info":[{"award-number":["21877101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008327","name":"Zhejiang University of Technology","doi-asserted-by":"publisher","award":["2024122"],"award-info":[{"award-number":["2024122"]}],"id":[{"id":"10.13039\/501100008327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017599","name":"Science and Technology Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2018R01015"],"award-info":[{"award-number":["2018R01015"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118183","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:22:17Z","timestamp":1758576137000},"page":"118183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Research progress of TRK inhibitors and their structure-activity relationship"],"prefix":"10.1016","volume":"301","author":[{"given":"Yao-Yao","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Xuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-6004","authenticated-orcid":false,"given":"Guo-Wu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118183_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.118183_bib2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/319743a0","article-title":"A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences","volume":"319","author":"Martin-Zanca","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118183_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118183_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","article-title":"Repotrectinib: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118183_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ejmech.2025.118183_bib6","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-2954A","article-title":"A potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants","volume":"76","author":"Kozaki","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib7","doi-asserted-by":"crossref","first-page":"E297","DOI":"10.1073\/pnas.1611577114","article-title":"Structural characterization of nonactive site, TrkA-selective kinase inhibitors","volume":"114","author":"Su","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118183_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bmcl.2017.01.056","article-title":"The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity","volume":"27","author":"Furuya","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118183_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1021\/acs.jmedchem.8b00280","article-title":"Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors","volume":"62","author":"Bagal","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jmb.2012.08.002","article-title":"The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition","volume":"423","author":"Bertrand","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118183_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejmech.2025.118183_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103957","article-title":"NTRK fusions in thyroid cancer: pathology and clinical aspects","volume":"184","author":"Ma","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2025.118183_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/ijms21030753","article-title":"NTRK fusions in central nervous system tumors: a rare, but worthy target","volume":"21","author":"Gambella","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118183_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118183_bib15","article-title":"Editorial: molecular mechanisms of nociception, front. Molec","volume":"15","author":"Goudet","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2025.118183_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: a bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118183_bib17","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbr.2012.03.010","article-title":"Infusion of BDNF into the nucleus accumbens of aged rats improves cognition and structural synaptic plasticity through PI3K-ILK-Akt signaling","volume":"231","author":"Li","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib18","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/j.1460-2075.1996.tb00698.x","article-title":"A splice variant of the neurotrophin receptor trkB with increased specificity for brain-derived neurotrophic factor","volume":"15","author":"Strohmaier","year":"1996","journal-title":"EMBO (Eur. Mol. Biol. Organ.) J."},{"key":"10.1016\/j.ejmech.2025.118183_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118183_bib21","first-page":"4705","article-title":"A novel ETV6-NTRK3 gene fusion in primary renal fibrosarcoma","volume":"26","author":"Jiang","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118183_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib23","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","volume":"2","author":"Farago","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118183_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semcancer.2005.01.003","article-title":"ETV6-NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages","volume":"15","author":"Lannon","year":"2005","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118183_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejmech.2025.118183_bib27","doi-asserted-by":"crossref","first-page":"djv306","DOI":"10.1093\/jnci\/djv306","article-title":"Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer","volume":"108","author":"Sartore-Bianchi","year":"2016","journal-title":"JNCI-J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.118183_bib28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.molonc.2014.06.001","article-title":"The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition","volume":"8","author":"Ardini","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib29","doi-asserted-by":"crossref","first-page":"VIII16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib30","doi-asserted-by":"crossref","first-page":"VIII5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib32","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1172\/JCI120787","article-title":"Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies","volume":"128","author":"Taylor","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118183_bib33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-018-0622-4","article-title":"Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib34","doi-asserted-by":"crossref","first-page":"35809","DOI":"10.18632\/oncotarget.26260","article-title":"Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors","volume":"9","author":"Sigal","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118183_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAS.0b013e318231542a","article-title":"Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity","volume":"36","author":"Connor","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ejmech.2025.118183_bib36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12253-019-00685-2","article-title":"Methods for identifying patients with tropomyosin receptor kinase (TRK) fusion cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib37","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions: merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41379-021-00913-8","article-title":"NTRK insights: best practices for pathologists","volume":"35","author":"Hechtman","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejmech.2025.118183_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ejmech.2025.118183_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016871","article-title":"Functional characterization of human cancer-derived TRKB mutations","volume":"6","author":"Geiger","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118183_bib41","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/PAS.0000000000001062","article-title":"Pan-trk immunohistochemistry identifies NTRK rearrangements in pediatric mesenchymal tumors","volume":"42","author":"Rudzinski","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ejmech.2025.118183_bib42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2217\/14796694.1.5.689","article-title":"Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma","volume":"1","author":"Tacconelli","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib43","doi-asserted-by":"crossref","first-page":"8655","DOI":"10.1128\/MCB.20.23.8655-8666.2000","article-title":"Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia","volume":"20","author":"Reuther","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118183_bib44","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/onc.2009.61","article-title":"TrkA overexpression enhances growth and metastasis of breast cancer cells","volume":"28","author":"Lagadec","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118183_bib45","first-page":"1802","article-title":"Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells","volume":"62","author":"Eggert","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118183_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118183_bib48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1570180815666180803125935","article-title":"Synthesis and biological evaluation of some novel thiophene-bearing quinazoline derivatives as EGFR inhibitors","volume":"16","author":"Zou","year":"2019","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.ejmech.2025.118183_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2019.1538796","article-title":"Larotrectinib for the treatment of TRK fusion solid tumors","volume":"19","author":"Laetsch","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2025.118183_bib50","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118183_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17512433.2019.1661775","article-title":"Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer","volume":"12","author":"Federman","year":"2019","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118183_bib53","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1021\/acs.jmedchem.0c00345","article-title":"Synthetic approaches to new drugs approved during 2018","volume":"63","author":"Flick","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib54","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib55","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpba.2018.07.032","article-title":"LC-MS\/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation","volume":"160","author":"Attwa","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2025.118183_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118183_bib58","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118183_bib60","article-title":"Total synthesis of entrectinib with key photo-redox mediated cross-coupling in flow","volume":"2022","author":"Cordell","year":"2022","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib61","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118183_bib62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118183_bib63","doi-asserted-by":"crossref","first-page":"15540","DOI":"10.1021\/acs.jmedchem.2c01361","article-title":"Targeting gatekeeper mutations for kinase drug discovery","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cancergen.2022.01.004","article-title":"The promise of TRK inhibitors in pediatric cancers with NTRK fusions","volume":"262\u2013263","author":"Blauel","year":"2022","journal-title":"Cancer Genet."},{"key":"10.1016\/j.ejmech.2025.118183_bib65","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1158\/1535-7163.MCT-21-0632","article-title":"Molecular characteristics of Repotrectinib that enable potent inhibition of TRK fusion proteins and resistant mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118183_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128646","article-title":"Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: design, synthesis and biological evaluation","volume":"63","author":"Fan","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118183_bib67","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118183_bib68","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3390\/pharmaceutics13111761","article-title":"ABCB1 and ABCG2 control brain accumulation and intestinal disposition of the novel ROS1\/TRK\/ALK inhibitor Repotrectinib, while OATP1A\/1B, ABCG2, and CYP3A limit its oral availability","volume":"13","author":"Li","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.118183_bib69","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib70","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.3390\/molecules29153560","article-title":"Pyrazolo[1,5-a] pyrimidine as a prominent framework for tropomyosin receptor kinase (Trk) inhibitors-synthetic strategies and SAR insights","volume":"29","author":"Mahajan","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118183_bib71","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118183_bib72","article-title":"Taletrectinib adipate","year":"2025","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejmech.2025.118183_bib73","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-20-1630","article-title":"US phase I first-in-human study of Taletrectinib (DS-6051b\/AB-106), a ROS1\/TRK inhibitor, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib74","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/2159-8290.CD-20-0571","article-title":"TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118183_bib75","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s42003-020-01508-w","article-title":"NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors","volume":"3","author":"Somwar","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejmech.2025.118183_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107994","article-title":"Inhibition of MEK1\/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-driven cancer","volume":"32","author":"Vaishnavi","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118183_bib77","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118183_bib78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/PO.19.00287","article-title":"Response and mechanisms of resistance to Larotrectinib and Selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1","volume":"4","author":"Hemming","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib79","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/1538-7445.AM2019-2198","article-title":"Abstract 2198: PBI-200: a novel, brain penetrant, next generation pan-TRK kinase inhibitor","volume":"79","author":"Regina","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118183_bib80","doi-asserted-by":"crossref","first-page":"vi181","DOI":"10.1093\/neuonc\/noab196.719","article-title":"EXTH-80. PBI-200: IN VIVO efficacy of a novel, highly CNS-penetrant next generation TRK inhibitor","volume":"23","author":"Pal","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib81","series-title":"Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 from FDA. News Release","year":"2022"},{"key":"10.1016\/j.ejmech.2025.118183_bib82","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41416-024-02760-1","article-title":"Zurletrectinib is a next-generationTRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents","volume":"131","author":"Roa","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118183_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3106","article-title":"Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor","volume":"40","author":"Wei","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118183_bib84","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the next-generation pan-TRK kinase inhibitors for the treatment of cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib85","first-page":"3081","article-title":"First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma","volume":"39","author":"Chung","year":"2021","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2025.118183_bib86","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1021\/jm061112p","article-title":"Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of tie-2 kinase","volume":"50","author":"Cee","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib87","series-title":"Pyrrolidinyl Urea and Pyrrolidinyl Thiourea Compounds as TRKA Kinase Inhibitors","author":"Allen","year":"2012"},{"key":"10.1016\/j.ejmech.2025.118183_bib88","first-page":"E297","article-title":"Structural characterization of nonactive site, TrkA-selective kinase inhibitors","volume":"vol.114","author":"Su","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118183_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114022","article-title":"Discovery of novel TrkA allosteric inhibitors: structure-based virtual screening, biological evaluation and preliminary SAR studies","volume":"228","author":"Guo","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114838","article-title":"A bibliometric analysis of PROTAC from 2001 to 2021","volume":"244","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib91","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1021\/acs.jmedchem.0c01947","article-title":"Selectively targeting tropomyosin receptor kinase A (TRKA) via PROTACs","volume":"63","author":"Xiang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib93","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1038\/s41598-023-31055-3","article-title":"Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours","volume":"13","author":"O'Haire","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118183_bib94","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/acs.molpharmaceut.9b00673","article-title":"TrkC-targeted kinase inhibitors and PROTACs","volume":"16","author":"Zhao","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118183_bib95","series-title":"Tropomyosin Receptor Kinase (Trk) Degradation Compounds and Methods of Use","author":"Liu","year":"2021"},{"key":"10.1016\/j.ejmech.2025.118183_bib96","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1021\/acsmedchemlett.5b00050","article-title":"(R)-2-Phenylpyrrolidine substituted imidazopyridazines: a new class of potent and selective pan-TRK inhibitors","volume":"6","author":"Choi","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118183_bib97","series-title":"Substituted Pyrazolo[1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors","author":"Haas","year":"2010"},{"key":"10.1016\/j.ejmech.2025.118183_bib98","series-title":"Substituted Pyrazolo [1,5-a] Pyrimidine Compounds as TRK Kinase Inhibitors","author":"Allen","year":"2011"},{"key":"10.1016\/j.ejmech.2025.118183_bib99","series-title":"Substituted (2-Azabicyclo [3.1.0] Hexan-2-Yl) Pyrazolo [1, 5-a] Pyrimidine and Imidazo [1, 2-b] Pyridazine Compounds as Trk Kinases Inhibitors","author":"Liu","year":"2019"},{"key":"10.1016\/j.ejmech.2025.118183_bib100","series-title":"Macrocyclic Compounds as TRK Kinase Inhibitors","author":"Andrews","year":"2011"},{"key":"10.1016\/j.ejmech.2025.118183_bib101","series-title":"Compound Having Macrocyclic Molecular Structure and Use Thereof","author":"Lin","year":"2019"},{"key":"10.1016\/j.ejmech.2025.118183_bib102","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib103","first-page":"11","article-title":"The roles of computer-aided drug synthesis in drug development","volume":"3","author":"Jia","year":"2022","journal-title":"Green Synth. Catal."},{"key":"10.1016\/j.ejmech.2025.118183_bib104","doi-asserted-by":"crossref","first-page":"12427","DOI":"10.1021\/acs.jmedchem.2c01099","article-title":"Discovery of CH7057288 as an orally bioavailable, selective, and potent pan-TRK inhibitor","volume":"65","author":"Ito","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib105","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-17-1180","article-title":"Selective TRK inhibitor CH7057288 against TRK fusion-driven cancer","volume":"17","author":"Tanaka","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118183_bib106","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the first highly selective and broadly effective macrocycle-based type II TRK inhibitors that overcome clinically acquired resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib107","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1021\/acs.jmedchem.3c00899","article-title":"Structure-based optimization of the third generation type II macrocycle TRK inhibitors with improved activity against solvent-front, xDFG, and gatekeeper mutations","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-06246-5","article-title":"A novel c-Met\/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation","volume":"14","author":"An","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118183_bib109","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acs.jmedchem.3c01645","article-title":"Discovery, optimization, and evaluation of novel Pyridin-2(1H)-one analogues as potent TRK inhibitors for cancer treatment","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib110","doi-asserted-by":"crossref","first-page":"11484","DOI":"10.1021\/acs.jmedchem.5c00412","article-title":"Structural optimization of next-generation TRK inhibitors against acquired drug resistance mutations for the treatment of solid tumors","volume":"68","author":"Xu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115953","article-title":"Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance","volume":"264","author":"Qin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118183_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117231","article-title":"Design, synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK Inhibitors","volume":"285","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:40:07Z","timestamp":1773132007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":112,"alternative-id":["S0223523425009481"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118183","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress of TRK inhibitors and their structure-activity relationship","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118183"}}